In:
International Journal of Alzheimer's Disease, Hindawi Limited, Vol. 2010 ( 2010), p. 1-11
Abstract:
Background . Patients afflicted with Alzheimer's disease (AD) exhibit a decrease in the cerebrospinal fluid (CSF) concentration of the 42 amino acid form of β -amyloid ( A β 42 ). However, a high discrepancy between different centers in measured A β 42 levels reduces the utility of this biomarker as a diagnostic tool and in monitoring the effect of disease modifying drugs. Preanalytical and analytical confounding factors were examined with respect to their effect on the measured A β 42 level. Methods . Aliquots of CSF samples were either treated differently prior to A β 42 measurement or analyzed using different commercially available xMAP or ELISA assays. Results . Confounding factors affecting CSF A β 42 levels were storage in different types of test tubes, dilution with detergent-containing buffer, plasma contamination, heat treatment, and the origin of the immunoassays used for quantification. Conclusion . In order to conduct multicenter studies, a standardized protocol to minimize preanalytical and analytical confounding factors is warranted.
Type of Medium:
Online Resource
ISSN:
2090-0252
Language:
English
Publisher:
Hindawi Limited
Publication Date:
2010
detail.hit.zdb_id:
2573333-3
Bookmarklink